Market closed
SCYNEXIS/$SCYX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SCYNEXIS
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Ticker
$SCYX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
28
Website
SCYNEXIS Metrics
BasicAdvanced
$36M
-
-$0.44
1.67
-
Price and volume
Market cap
$36M
Beta
1.67
52-week high
$3.07
52-week low
$0.73
Average daily volume
120K
Financial strength
Current ratio
2.995
Quick ratio
2.887
Long term debt to equity
3.949
Total debt to equity
29.54
Interest coverage (TTM)
-14.53%
Management effectiveness
Return on assets (TTM)
-21.18%
Return on equity (TTM)
-33.25%
Valuation
Price to revenue (TTM)
11.819
Price to book
0.63
Price to tangible book (TTM)
0.63
Price to free cash flow (TTM)
-1.844
Growth
Revenue change (TTM)
-97.33%
Earnings per share change (TTM)
-131.65%
3-year revenue growth (CAGR)
-34.22%
3-year earnings per share growth (CAGR)
-29.39%
What the Analysts think about SCYNEXIS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for SCYNEXIS stock.
SCYNEXIS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SCYNEXIS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SCYNEXIS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for SCYNEXIS stock?
SCYNEXIS (SCYX) has a market cap of $36M as of April 17, 2025.
What is the P/E ratio for SCYNEXIS stock?
The price to earnings (P/E) ratio for SCYNEXIS (SCYX) stock is 0 as of April 17, 2025.
Does SCYNEXIS stock pay dividends?
No, SCYNEXIS (SCYX) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next SCYNEXIS dividend payment date?
SCYNEXIS (SCYX) stock does not pay dividends to its shareholders.
What is the beta indicator for SCYNEXIS?
SCYNEXIS (SCYX) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.